Español
India
Italiano
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Cybin
CYBN
AMEX
Watchlist
Get Report
Perks
Buy
Compare Brokers
$0.271000
0.0065
2.46%
At Close: -
15 minutes delayed
Get Report
Watch
Q4 2023 Earnings were released on Wed Jun 26th, before the market open
Cybin (CYBN) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Cybin (AMEX:CYBN) Stock
Cybin Stock (AMEX: CYBN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, June 26, 2024
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Patricio Liddle
Cybin Q4 Net Loss C$21M Vs. C$14M YoY, Cash T...
Benzinga Newsdesk
Friday, June 21, 2024
Cantor Fitzgerald Reiterates Overweight on Cy...
Benzinga Newsdesk
Tuesday, June 18, 2024
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More
Jelena Martinovic
Wednesday, June 12, 2024
'Oregon's First-In-Nation Psilocybin Industry...
Benzinga Newsdesk
Wednesday, June 05, 2024
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
Aaron Bry
Shares of psychedelics companies are trading ...
Benzinga Newsdesk
Thursday, May 16, 2024
HC Wainwright & Co. Reiterates Buy on Cybin, ...
Benzinga Newsdesk
Thursday, May 09, 2024
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Nina Zdinjak
Tuesday, May 07, 2024
"FDA Expert Committee Will Review MDMA-Assist...
Benzinga Newsdesk
Monday, May 06, 2024
Cybin Provides Corporate Update And Highlight...
Benzinga Newsdesk
Tuesday, April 16, 2024
Cybin Announces Grant Of Additional US Patent...
Benzinga Newsdesk
Saturday, March 30, 2024
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Lara Goldstein
Wednesday, March 20, 2024
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Lara Goldstein
Friday, March 15, 2024
Cybin Says It Initiated Phase 2 Proof-of-Conc...
Benzinga Newsdesk
Thursday, March 14, 2024
Reported Earlier, 'Indiana Lawmakers Send Psi...
Benzinga Newsdesk
Cybin Announces End-of-Phase 2 Meeting with F...
Benzinga Newsdesk
Wednesday, March 13, 2024
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Lara Goldstein
HC Wainwright & Co. Maintains Buy on Cybin, M...
Benzinga Newsdesk
Cybin Receives FDA Breakthrough Therapy Desig...
Benzinga Newsdesk
Monday, March 04, 2024
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Lara Goldstein
Friday, February 16, 2024
Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss
The Dales Report
Thursday, February 15, 2024
HC Wainwright & Co. Reiterates Buy on Cybin, ...
Benzinga Newsdesk
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Lara Goldstein
Wednesday, February 14, 2024
Cybin Says Net Loss Was C$30.3 Million For Q3...
Benzinga Newsdesk
Monday, February 12, 2024
'FDA Grants Priority Review Of MDMA-Assisted ...
Benzinga Newsdesk
Wednesday, February 07, 2024
Cybin Reveals Grant Of Two Additional Patents...
Benzinga Newsdesk
Saturday, January 27, 2024
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
Lara Goldstein
Tuesday, January 23, 2024
FDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized Anxiety
Lara Goldstein
Monday, January 15, 2024
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Lara Goldstein
Friday, January 12, 2024
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Lara Goldstein
Wednesday, January 10, 2024
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
Lara Goldstein
Tuesday, January 09, 2024
Cybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results
Lara Goldstein
Monday, January 08, 2024
'New Bipartisan Washington Bill Would Legaliz...
Benzinga Newsdesk
Cybin Announces Topline Data from Phase 1 Stu...
Benzinga Newsdesk
Saturday, January 06, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Maureen Meehan
Thursday, January 04, 2024
"DEA Confirms That Psychedelic Mushroom Spore...
Benzinga Newsdesk
Cybin's Phase 2 Results Boost Psychedelic-Bas...
Benzinga Newsdesk
Monday, January 01, 2024
Psychedelic Stock Gainers And Losers From January 1, 2024
Benzinga Insights
Wednesday, December 13, 2023
More Protocols And Guidance Are Needed As Momentum Builds For Veterans, Psychedelics, And Mental Health
Andre Bourque
Wednesday, December 06, 2023
Cybin Announces Grant of Additional U.S. Pate...
Benzinga Newsdesk
Tuesday, December 05, 2023
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Lara Goldstein
Sunday, December 03, 2023
Cybin's Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What's Next?
Lara Goldstein
Thursday, November 30, 2023
Cybin Says CYB003 Showed Clear Incremental Be...
Benzinga Newsdesk
Cybin Reports Phase 2 Topline Safety, Efficac...
Benzinga Newsdesk
Friday, November 24, 2023
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
Lara Goldstein
Thursday, November 23, 2023
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Benzinga Insights
Monday, November 20, 2023
Cybin Will Discuss Its Topline Phase 2 Safety...
Benzinga Newsdesk
Friday, November 17, 2023
Analyst Expectations for Cybin's Future
Benzinga Insights
Expedia To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Friday
Lisa Levin
Show More
